US ETFDetailed Quotes
XBI SPDR S&P Biotech ETF
- 81.100
- -3.300-3.91%
Close Mar 31 16:00 ET
81.660High79.325Low
81.660High79.325Low16.66MVolume81.510Open84.400Pre Close1.34BTurnover26.41%Turnover Ratio--P/E (Static)63.08MShares105.45952wk High--P/B5.12BFloat Cap79.32552wk Low0.14Dividend TTM63.08MShs Float174.444Historical High0.17%Div YieldTTM2.77%Amplitude21.346Historical Low80.571Avg Price1Lot Size
I will start with QQQ/ND and VIX, and then I will move to individual stocks. I don't own these and don't necessarily recommend buying them. I use them as sentiment and market bias/direction indicators.
I will be upfront and say my bias is up. How high doesn't really matter to me. I don't own the MAG 7. I just want to see willing buyers. I'm not nieve and am hedged for downside. but I have been buying a lot of individual ...
SYNTHETIC Stock ON XBI
The SPDR S&P Biotech ETF (XBI) is an equal-weighted ETF that tracks the S&P Biotechnology Select Industry Index. Unlike market-cap-weighted ETFs, XBI gives equal exposure to small, mid, and large biotech stocks. This makes it more volatile compared to other biotech ETFs like IBB, which is more weighted toward large-cap biotech firms.
XBI Price Action Analysis
– XBI has been on...
Big picture: Janux's stock has been volatile, trading near its 52-week low. Investor sentiment remains cautious amidst broader biotech sector challenges.
Key Developments:
📊 Positive Clinical Data: JANX007 showed impressive results in Phase 1 trials for metastatic castration-resistant prost...
Market Scorecard
Market is weak with NQ dropping more than 7% and ES more by 5%. On contrast HSI has remained strong in anticipation of positive news flows coming out from the CCP Meetings in China, ongoing.
Trade Scorecard
IBIT Call Ratio (Update)
IBIT has hit roller coaster with selloff to a low of $46.07. Price has since recovered to $51.44.
We closed the short call 57C on 27 February when IBIT hit lows of $46.90 for $0...
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...
No comment yet